Skip to main content
OpenTrials
Completed

NCT Number: NCT01153997

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

This trial is conducted in Japan. The aim of this trial is to investigate the safety profile of recombinant factor XIII (rFXIII) assessed by the occurrence of adverse events in healthy Japanese subjects. In addition pharmacokinetic parameters will be investigated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Fukuoka, 812-0025, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Good general health based on assessment of medical history, physical examination, ECG (electrocardiogram) and clinical laboratory data at screening, as judged by the physician
  • Body mass index (BMI) between 18.0-27.0 kg/m2 (both inclusive)

Exclusion criteria

  • The receipt of any investigational products for coagulation factor protein within 6 months prior to trial start (screening)
  • Known or suspected allergy to yeast
  • Known bleeding or hematologic disorder
  • Significant history of alcoholism or drug/chemical abuse as judged by the physician or positive result in the alcohol breath test/screen of drugs at the trial start (screening)
  • Smoking more than 10 cigarettes/day or equivalent
  • Not able or willing to refrain from smoking whenever required for the trial procedures
  • Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the physician
  • Excessive consumption of a diet deviating from a normal diet as judged by the physician
  • Strenuous exercise as judged by the physician within 4 days prior to trial start (screening)
  • Surgery or trauma with significant blood loss (500 mL or more blood) within 3 months prior to trial start (screening)
  • Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods. Adequate contraceptive measures include that the subject uses a condom during intercourse or that the partner practices adequate conception (sterilisation, hormonal intrauterine devices and oral contraceptives).

Treatment and study plan

catridecacog

Drug

Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.

Placebo

Drug

Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.

Primary outcomes

  1. Occurrence of serious adverse events

    Time frame: from first trial related activity (visit 1) and up to 28 days (visit 8) after dosing

  2. Occurrence of non-serious adverse events

    Time frame: from first trial related activity (visit 1) and up to 28 days (visit 8) after dosing

Secondary outcomes

  1. AUC (area under the curve) from time zero to 28 days

    Time frame: at day 28

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

A Randomised, Placebo-controlled Single-dose, Parallel-group, Double-blind Trial Evaluating Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Japanese Subjects

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Jun 30, 2010
Registry last updated
Jun 18, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.